Hydronephrosis
Methodology & AI Transparency ⓘ
Hydronephrosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hydronephrosis is an ICD-10-CM indexed diagnosis (N13.30) within Prostate (BPH), Bladder & Urinary Tract.
- 2 Real-world patient consensus: Federal ICD-10-CM code N13.30 categorizes Hydronephrosis under Prostate (BPH), Bladder & Urinary Tract.
- 3 Typical cash cost range: Workup highlights for Hydronephrosis (N13.30): alpha-1 blockers [Hydronephrosis N13.30].
- 4 Top reported side effects / signs: Objective lab/clinical target for Hydronephrosis: Urinalysis & Post-Void in Hydronephrosis (N13.30: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N13.30)) and Total PSA & in Hydronephrosis (N13.30: Serum Creatinine/eGFR).
Ask our AI Specialists anything about Hydronephrosis
What Is Hydronephrosis?
Hydronephrosis is an ICD-10-CM indexed diagnosis (N13.30) within Prostate (BPH), Bladder & Urinary Tract. Clinical evaluation centers on alpha-1 blockers [Hydronephrosis N13.30] alongside serial Urinalysis & Post-Void in Hydronephrosis (N13.30: Residual (PVR)) tracking (Negative leukocyte/nitrite; PVR < 50 mL (N13.30)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in urology & prostate, Hydronephrosis (N13.30) involves or detrusor overactivity [Hydronephrosis N13.30]. progression correlates with shifts in Urinalysis & Post-Void in Hydronephrosis (N13.30: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N13.30)).
Common Symptoms & Clinical Signs
- • Presentation of Hydronephrosis (N13.30): weak, hesitant, or in Hydronephrosis (N13.30: intermittent urinary stream)
- • Secondary Hydronephrosis clinical sign: waking two or in Hydronephrosis (N13.30: more times nightly)
- • Symptom flares in Hydronephrosis correlating with Urinalysis & Post-Void in Hydronephrosis (N13.30: Residual (PVR)) deviation outside Negative leukocyte/nitrite; PVR < 50 mL (N13.30)
- • Functional urology & prostate impact requiring alpha-1 blockers [Hydronephrosis N13.30] evaluation (N13.30)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hydronephrosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N13.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Hydronephrosis (N13.30: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N13.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Hydronephrosis (N13.30: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N13.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Hydronephrosis (N13.30: Score) | 0 – 7 (mild symptoms) (N13.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hydronephrosis
Treatment selection for Hydronephrosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hydronephrosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Rilzabrutinib was well-tolerated, with similar side effects reported in both groups. The Journal of investigative dermatology • 2024-08-15 • Phase III Randomized Trial | N = 65 | 88/100 | PMID 38493933 ↗ |
| Can This Approach Help? Inside the Latest Research on Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings. International journal of hematology • 2024-09-15 • Phase III Randomized Trial | N = 13 | 82/100 | PMID 38888812 ↗ |
| Can This Approach Help? Inside the Latest Research on Multicenter noninferiority phase III clinical trial of the first biosimilar of The data obtained confirm that the Biosimilar is not inferior to the Originator in terms of the main efficacy parameter, and is also comparable with it in terms of safety and additional efficacy parameters. Annals of hematology • 2021-11-15 • Phase III Randomized Trial | N = 16 | 82/100 | PMID 34398258 ↗ |
Hydronephrosis Patient Community & “People Like Me” Threads
Filter Hydronephrosis community threads and patient logs by age, biological sex, dosage, and treatment duration.